Northern Trust
BDTX icon

Northern Trust’s Black Diamond Therapeutics BDTX Stock Holding History

Northern Trust’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$676K Sell
365,394
-99,314
-21% -$243K ﹤0.01% 3593
2026
Q1 		$990K Sell
464,708
-7,994
-2% -$19K ﹤0.01% 3345
2025
Q4 		$1.15M Sell
472,702
-15,362
-3% -$54.4K ﹤0.01% 3298
2025
Q3 		$1.85M Buy
488,064
+336,643
+222% +$985K ﹤0.01% 3076
2025
Q2 		$376K Sell
151,421
-226,789
-60% -$437K ﹤0.01% 3746
2025
Q1 		$586K Sell
378,210
-4,537
-1% -$9.51K ﹤0.01% 3509
2024
Q4 		$819K Buy
382,747
+37,633
+11% +$108K ﹤0.01% 3473
2024
Q3 		$1.5M Buy
345,114
+220,960
+178% +$1.2M ﹤0.01% 3163
2024
Q2 		$579K Buy
124,154
+20,122
+19% +$108K ﹤0.01% 3452
2024
Q1 		$527K Sell
104,032
-5,657
-5% -$22.8K ﹤0.01% 3544
2023
Q4 		$308K Buy
109,689
+40,269
+58% +$94.5K ﹤0.01% 3711
2023
Q3 		$199K Buy
69,420
+31,529
+83% +$116K ﹤0.01% 3816
2023
Q2 		$191K Sell
37,891
-92
-0.2% -$188 ﹤0.01% 3850
2023
Q1 		$71.8K Hold
37,983
– – ﹤0.01% 4169
2022
Q4 		$68.4K Hold
37,983
– – ﹤0.01% 4204
2022
Q3 		$64K Buy
37,983
+145
+0.4% +$447 ﹤0.01% 4252
2022
Q2 		$93K Sell
37,838
-152,108
-80% -$354K ﹤0.01% 4200
2022
Q1 		$527K Sell
189,946
-11,509
-6% -$42K ﹤0.01% 3719
2021
Q4 		$1.07M Sell
201,455
-1,999
-1% -$14K ﹤0.01% 3512
2021
Q3 		$1.72M Sell
203,454
-6,833
-3% -$67.5K ﹤0.01% 3359
2021
Q2 		$2.56M Buy
210,287
+16,543
+9% +$327K ﹤0.01% 3240
2021
Q1 		$4.7M Sell
193,744
-10,276
-5% -$277K ﹤0.01% 2784
2020
Q4 		$6.54M Sell
204,020
-1,723
-0.8% -$56.6K ﹤0.01% 2518
2020
Q3 		$6.22M Buy
205,743
+74,398
+57% +$2.26M ﹤0.01% 2396
2020
Q2 		$5.54M Buy
131,345
+8,839
+7% +$325K ﹤0.01% 2453
2020
Q1 		$3.06M Buy
+122,506
New +$3.73M ﹤0.01% 2603

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust's BDTX Position: Q2 2026 in Review

Northern Trust reduced its Black Diamond Therapeutics (BDTX) stake by 21% in Q2 2026, selling an estimated $243K and leaving 365,394 shares worth $676K. The position accounts for ﹤0.01% of the portfolio, ranked #3593.

Northern Trust first reported a position in BDTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $6.54M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Northern Trust held 365,394 shares of Black Diamond Therapeutics worth $676K as of Q2 2026.
  • Northern Trust sold 99,314 Black Diamond Therapeutics shares in Q2 2026, an estimated $243K.
  • Black Diamond Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3593 holding.
  • Northern Trust first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Northern Trust's Black Diamond Therapeutics position peaked at $6.54M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.